CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 67 enrolled
Drug / intervention
BIA 2-093 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02283788
NCT02283788Phase 1Completed
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women

Bial - Portela C S.A.·interventional·Posted Nov 5, 2014·Updated Apr 11, 2025

In Brief

A Phase 1 clinical trial evaluating BIA 2-093, Moxifloxacin, and 1 other intervention for Epilepsy. Completed, enrolled 67 participants across 1 site.

Detailed Summary

A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 5, 2014
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.7 years ago

Interventions

BIA 2-093drug

Moxifloxacindrug

Placebodrug